Quantcast
Published On: Fri, Jan 9th, 2015

Blood clot prevention drug, Savaysa, gets FDA approval

The U.S. Food and Drug Administration today approved the anti-clotting drug Savaysa (edoxaban tablets) to reduce the risk of stroke and dangerous blood clots (systemic embolism) in patients with atrial fibrillation that is not caused by a heart valve problem.

blood clot

IMAGE/National Heart Lung and Blood Institute (NIH)

Atrial fibrillation is one of the most common types of abnormal heart rhythm. It occurs when the heart’s two upper chambers (atria) do not contract properly, allowing blood clots to form, which can break off and travel to the brain or other parts of the body. Patients with atrial fibrillation experience an abnormal, irregular and rapid heartbeat.

Savaysa also has been approved to treat deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients who have already been treated with an anti-clotting drug administered by injection or infusion (parenterally), for five to ten days.

DVT is a blood clot that forms in a vein deep in the body, usually in the lower leg or thigh. A potentially deadly condition called PE results when a blood clot in a deep vein breaks off and travels to an artery in the lungs and blocks blood flow.

“In patients with atrial fibrillation, anti-clotting drugs lower the risk of stroke by helping to prevent blood clots from forming in the heart,” said Norman Stockbridge, M.D., Ph.D., director of the Division of Cardiovascular and Renal Products in the FDA’s Center for Drug Evaluation and Research. “It is important to have a variety of these types of drugs available as options for patients.”

The safety and efficacy of Savaysa in treating patients with atrial fibrillation not caused by cardiac valve disease was studied in a clinical trial of 21,105 participants. The trial compared two dose levels of Savaysa with the anti-clotting drug warfarin for their effects on rates of stroke and dangerous blood clots (systemic emboli). The trial results showed the higher dose of Savaysa to be similar to warfarin for the reduction in the risk of stroke.   While warfarin is highly effective in reducing the risk of stroke in patients with atrial fibrillation, it increases the risk of bleeding. Savaysa demonstrated significantly less major bleeding compared to warfarin.

Savaysa for treatment of patients with DVT and PE was studied in 8,292 participants. The study compared the safety and efficacy of Savaysa to warfarin for treating patients with a DVT and/or PE to reduce the rate of recurrence of symptomatic venous thromboembolism (VTE) events (which includes DVT, PE, and VTE- related death).  In the trial, 3.2 percent of participants taking Savaysa had a symptomatic recurrent VTE compared to 3.5 percent of those taking warfarin.

The most common side effects observed in clinical trial participants were bleeding and anemia. As with other FDA-approved anti-clotting drugs, bleeding, including life-threatening bleeding, is the most serious risk with Savaysa. There is no treatment that has been proven to reverse the anti-coagulant effect of Savaysa.

Savaysa has a Boxed Warning that provides important dosing and safety information for health care professionals about specific patient groups, including a warning that Savaysa is less effective in atrial fibrillation patients with a creatinine clearance greater than 95 milliliters per minute. A patient’s level of creatinine clearance shows how well a patient’s kidneys are working by measuring the level of the waste product creatinine in the blood or urine. This should be assessed before initiating therapy with Savaysa. Patients with creatinine clearance greater than 95 milliliters per minute have an increased risk of stroke compared to similar patients given warfarin. Savaysa should not be used in nonvalvular atrial fibrillation patients with a higher creatinine clearance. Another anticoagulant should be used instead.

As with other anticoagulants, the Boxed Warning counsels that premature discontinuation of Savaysa increases the risk of stroke and notes that spinal or epidural hematomas (collection of blood outside of a blood vessel) may occur in patients treated with Savaysa who are receiving anesthesia injected around the spine or undergoing spinal puncture.

Savaysa will be dispensed with a patient Medication Guide that provides instructions on its use and drug safety information. Health care professionals should counsel patients about the increased risk of bleeding for those taking this product.

Savaysa is made by Tokyo-based Daiichi Sankyo Co., Ltd.

On the DISPATCH: Headlines  Local  Opinion

Subscribe to Weekly Newsletter

* indicates required
/ ( mm / dd ) [ALL INFO CONFIDENTIAL]

About the Author

- The generic Dispatch designation, used primarily for press releases or syndicated content, but may be used for guest author requesting a generic nomenclature

Tags
Displaying 3 Comments
Have Your Say
  1. Blood-Thinning Drug Savaysa Approved – Philly.com | Amazing News says:

    […] The Global Dispatch […]

  2. FDA OKs New Anti-Clotting Drug for Type of AFib – WebMD | Amazing News says:

    […] The Global Dispatch […]

  3. FDA Approves New Oral Anticoagulant From Daiichi Sankyo – Forbes | Health News says:

    […] The Global Dispatch […]

Leave a comment

XHTML: You can use these html tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

Sign up for our Weekly Newsletter



Recent Posts

October 15, 2019, Comments Off on

October 15, 2019, Comments Off on

October 15, 2019, Comments Off on

October 15, 2019, Comments Off on

October 15, 2019, Comments Off on

October 15, 2019, Comments Off on

Categories

Archives

At the Movies



Pin It